Table 1.
Demographic, clinicopathological characteristics and treatment information of the training and validation cohorts
| Patient characteristics | nRT group (n=823) | non-NRT group (n=922) | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| Training cohort n=576 | validation cohort n=247 | χ2 | P | Training cohort n=645 | validation cohort n=277 | χ2 | P | |
| Age, years | 2.789 | 0.248 | 2.507 | 0.286 | ||||
| <50 | 65 (11.3) | 34 (13.8) | 56 (8.7) | 33 (11.9) | ||||
| 50-71 | 429 (74.5) | 170 (68.8) | 416 (64.5) | 176 (63.5) | ||||
| >71 | 82 (14.2) | 43 (17.4) | 173 (26.8) | 68 (24.5) | ||||
| Gender | 0.088 | 0.766 | 0.021 | 0.886 | ||||
| Female | 91 (15.8) | 37 (15.0) | 119 (18.4) | 50 (18.1) | ||||
| Male | 485 (84.2) | 210 (85.0) | 526 (81.6) | 227 (81.9) | ||||
| Race | 1.487 | 0.475 | 0.386 | 0.825 | ||||
| Black | 22 (3.8) | 8 (3.2) | 36 (5.6) | 14 (5.1) | ||||
| White | 514 (89.2) | 227 (91.9) | 539 (83.6) | 236 (85.2) | ||||
| Others | 40 (6.9) | 12 (4.9) | 70 (10.9) | 27 (9.7) | ||||
| Grade | 3.263 | 0.353 | 0.938 | 0.816 | ||||
| G1 | 24 (4.2) | 10 (4.0) | 44 (6.8) | 19 (6.9) | ||||
| G2 | 200 (34.7) | 102 (41.3) | 228 (35.3) | 105 (37.9) | ||||
| G3 | 299 (51.9) | 115 (46.6) | 351 (54.4) | 146 (52.7) | ||||
| GX | 53 (9.2) | 20 (8.1) | 22 (3.4) | 7 (2.5) | ||||
| T stage | 1.052 | 0.789 | 2.387 | 0.496 | ||||
| T1 | 10 (1.7) | 6 (2.4) | 199 (30.9) | 87 (31.4) | ||||
| T2 | 82 (14.2) | 40 (16.2) | 94 (14.6) | 45 (16.2) | ||||
| T3 | 441 (76.6) | 184 (74.5) | 305 (47.3) | 132 (47.7) | ||||
| T4 | 43 (7.5) | 17 (6.9) | 47 (7.3) | 13 (4.7) | ||||
| N stage | 5.166 | 0.160 | 0.972 | 0.808 | ||||
| N0 | 162 (28.1) | 77 (31.2) | 294 (45.6) | 134 (48.4) | ||||
| N1 | 275 (47.7) | 99 (40.1) | 153 (23.7) | 63 (22.7) | ||||
| N2 | 108 (18.8) | 51 (20.6) | 101 (15.7) | 44 (15.9) | ||||
| N3 | 31 (5.4) | 20 (8.1) | 97 (15.0) | 36 (13.0) | ||||
| RLN | 0.201 | 0.654 | 0.804 | 0.370 | ||||
| <16 | 291 (50.5) | 129 (52.2) | 289 (44.8) | 133 (48.0) | ||||
| ≥33 | 285 (49.5) | 118 (47.8) | 356 (55.2) | 144 (52.0) | ||||
| Tumor size, mm | 4.354 | 0.113 | 0.417 | 0.812 | ||||
| <29 | 159 (27.6) | 73 (29.6) | 265 (41.1) | 108 (39.0) | ||||
| 29-42 | 191 (33.2) | 64 (25.9) | 164 (25.4) | 71 (25.6) | ||||
| >42 | 226 (39.2) | 110 (44.5) | 216 (33.5) | 98 (35.4) | ||||
| LNR, % | 3.317 | 0.190 | 2.224 | 0.329 | ||||
| <10 | 394 (68.4) | 167 (67.6) | 396 (61.4) | 179 (64.6) | ||||
| 10-30 | 117 (20.3) | 42 (17.0) | 117 (18.1) | 53 (19.1) | ||||
| >30 | 65 (11.3) | 38 (15.4) | 132 (20.5) | 45 (16.2) | ||||
| Therapy type | 0.400 | 0.819 | ||||||
| nRT+CT | 576 (100) | 247 (100) | ||||||
| aRT+CT | 145 (22.5) | 65 (23.5) | ||||||
| CT | 190 (29.5) | 76 (27.4) | ||||||
| none | 310 (48.1) | 136 (49.1) | ||||||
| TNM 7th stage | 7.451 | 0.281 | 8.778 | 0.186 | ||||
| IA | 12 (2.1) | 6 (2.4) | 113 (17.5) | 55 (19.9) | ||||
| IB | 24 (4.2) | 13 (5.3) | 85 (13.2) | 27 (9.7) | ||||
| IIA | 10 (1.7) | 9 (3.6) | 25 (3.9) | 10 (3.6) | ||||
| IIB | 170 (29.5) | 64 (25.9) | 112 (17.4) | 67 (24.2) | ||||
| IIIA | 216 (37.5) | 82 (33.2) | 116 (18.0) | 44 (15.9) | ||||
| IIIB | 97 (16.8) | 44 (17.8) | 73 (11.3) | 31 (11.2) | ||||
| IIIC | 47 (8.2) | 29 (11.7) | 121 (18.8) | 43 (15.5) | ||||
| TNM 8th stage | 6.694 | 0.153 | ||||||
| I | 46 (8.0) | 28 (11.3) | ||||||
| II | 113 (19.6) | 47 (19.0) | ||||||
| IIIA | 57 (9.9) | 17 (6.9) | ||||||
| IIIB | 313 (54.3) | 126 (51.0) | ||||||
| IVA | 47 (8.2) | 29 (11.7) | ||||||
Abbreviations: LNR, lymph node metastasis; RLN, number of removed lymph nodes; nRT, neoadjuvant radiotherapy; aRT, adjuvant radiotherapy; CT, chemotherapy.